Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-05-01 Epub Date: 2024-03-13 DOI:10.4103/sjg.sjg_27_24

Khalid Alswat, Riham Soliman, Nabiel N H Mikhail, Necati Örmeci, George N Dalekos, Moutaz F M Derbala, Said Ahmed Al-Busafi, Waseem Hamoudi, Gamal Shiha

{"title":"Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B.","authors":"Khalid Alswat, Riham Soliman, Nabiel N H Mikhail, Necati Örmeci, George N Dalekos, Moutaz F M Derbala, Said Ahmed Al-Busafi, Waseem Hamoudi, Gamal Shiha","doi":"10.4103/sjg.sjg_27_24","DOIUrl":null,"url":null,"abstract":"Background: We recently developed a simple novel index called fibrosis 6 (FIB-6) using machine learning data analysis. We aimed to evaluate its performance in the diagnosis of liver fibrosis and cirrhosis in chronic hepatitis B (CHB).Methods: A retrospective observational analysis of data was obtained from seven countries (Egypt, Kingdom of Saudi Arabia (KSA), Turkey, Greece, Oman, Qatar, and Jordan) of CHB patients. The inclusion criteria were receiving an adequate liver biopsy and a complete biochemical and hematological data. The diagnostic performance analysis of the FIB-6 index was conducted and compared with other non-invasive scores.Results: A total of 603 patients were included for the analysis; the area under the receiver operating characteristic curve (AUROC) of FIB-6 for the discrimination of patients with cirrhosis (F4), compensated advanced chronic liver disease (cACLD) (F3 and F4), and significant fibrosis (F2-F4) was 0.854, 0.812, and 0.745, respectively. The analysis using the optimal cut-offs of FIB-6 showed a sensitivity of 70.9%, specificity of 84.1%, positive predictive value (PPV) of 40.3%, and negative predictive value (NPV) of 95.0% for the diagnosis of cirrhosis. For the diagnosis of cACLD, the results were 71.5%, 69.3%, 40.8%, and 89.2%, respectively, while for the diagnosis of significant fibrosis, the results were 68.3%, 67.5%, 59.9%, and 75.0%, respectively. When compared to those of fibrosis 4 (FIB-4) index, aspartate aminotransferase (AST)-to-platelet ratio index (APRI), and AST-to-alanine aminotransferase (ALT) ratio (AAR), the AUROC for the performance of FIB-6 was higher than that of FIB-4, APRI, and AAR in all fibrosis stages. FIB-6 gave the highest sensitivity and NPV (89.1% and 92.4%) in ruling out cACLD and cirrhosis, as compared to FIB-4 (63.8% and 83.0%), APRI (53.9% and 86.6%), and AAR (47.5% and 82.3%), respectively.Conclusions: The FIB-6 index could be used in ruling out cACLD, fibrosis, and cirrhosis with good reliability.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11198916/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/sjg.sjg_27_24","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We recently developed a simple novel index called fibrosis 6 (FIB-6) using machine learning data analysis. We aimed to evaluate its performance in the diagnosis of liver fibrosis and cirrhosis in chronic hepatitis B (CHB).

Methods: A retrospective observational analysis of data was obtained from seven countries (Egypt, Kingdom of Saudi Arabia (KSA), Turkey, Greece, Oman, Qatar, and Jordan) of CHB patients. The inclusion criteria were receiving an adequate liver biopsy and a complete biochemical and hematological data. The diagnostic performance analysis of the FIB-6 index was conducted and compared with other non-invasive scores.

Results: A total of 603 patients were included for the analysis; the area under the receiver operating characteristic curve (AUROC) of FIB-6 for the discrimination of patients with cirrhosis (F4), compensated advanced chronic liver disease (cACLD) (F3 and F4), and significant fibrosis (F2-F4) was 0.854, 0.812, and 0.745, respectively. The analysis using the optimal cut-offs of FIB-6 showed a sensitivity of 70.9%, specificity of 84.1%, positive predictive value (PPV) of 40.3%, and negative predictive value (NPV) of 95.0% for the diagnosis of cirrhosis. For the diagnosis of cACLD, the results were 71.5%, 69.3%, 40.8%, and 89.2%, respectively, while for the diagnosis of significant fibrosis, the results were 68.3%, 67.5%, 59.9%, and 75.0%, respectively. When compared to those of fibrosis 4 (FIB-4) index, aspartate aminotransferase (AST)-to-platelet ratio index (APRI), and AST-to-alanine aminotransferase (ALT) ratio (AAR), the AUROC for the performance of FIB-6 was higher than that of FIB-4, APRI, and AAR in all fibrosis stages. FIB-6 gave the highest sensitivity and NPV (89.1% and 92.4%) in ruling out cACLD and cirrhosis, as compared to FIB-4 (63.8% and 83.0%), APRI (53.9% and 86.6%), and AAR (47.5% and 82.3%), respectively.

Conclusions: The FIB-6 index could be used in ruling out cACLD, fibrosis, and cirrhosis with good reliability.

查看原文本刊更多论文

FIB-6 评分在评估慢性乙型肝炎肝纤维化中的有效性。

背景：我们最近利用机器学习数据分析技术开发了一种简单的新指标，称为肝纤维化6（FIB-6）。我们旨在评估其在诊断慢性乙型肝炎（CHB）肝纤维化和肝硬化方面的性能：我们对七个国家（埃及、沙特阿拉伯王国、土耳其、希腊、阿曼、卡塔尔和约旦）的慢性乙型肝炎患者的数据进行了回顾性观察分析。纳入标准是接受过充分的肝脏活检以及完整的生化和血液学数据。对 FIB-6 指数进行了诊断性能分析，并与其他非侵入性评分进行了比较：共有 603 名患者被纳入分析；FIB-6 对肝硬化（F4）、代偿性晚期慢性肝病（cACLD）（F3 和 F4）和明显纤维化（F2-F4）患者的判别接收者操作特征曲线下面积（AUROC）分别为 0.854、0.812 和 0.745。使用 FIB-6 最佳临界值进行的分析表明，肝硬化诊断的灵敏度为 70.9%，特异度为 84.1%，阳性预测值为 40.3%，阴性预测值为 95.0%。诊断 cACLD 的结果分别为 71.5%、69.3%、40.8% 和 89.2%，而诊断明显纤维化的结果分别为 68.3%、67.5%、59.9% 和 75.0%。与纤维化4（FIB-4）指数、天冬氨酸氨基转移酶（AST）-血小板比值指数（APRI）和AST-丙氨酸氨基转移酶（ALT）比值指数（AAR）相比，在所有纤维化分期中，FIB-6的AUROC均高于FIB-4、APRI和AAR。与FIB-4（63.8%和83.0%）、APRI（53.9%和86.6%）和AAR（47.5%和82.3%）相比，FIB-6在排除cACLD和肝硬化方面的灵敏度和净现值（89.1%和92.4%）最高：FIB-6指数可用于排除cACLD、纤维化和肝硬化，其可靠性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.